Accenture Invests in Ryght AI to Transform Clinical Research with Agentic AI

The investment, through Accenture Ventures, targets faster patient access to new treatments by combining agentic AI with enterprise technology solutions.

Accenture has made a strategic investment in Ryght AI, a platform provider aimed at modernizing clinical research for the life sciences industry.

The investment, through Accenture Ventures, targets faster patient access to new treatments by combining agentic AI with enterprise technology solutions.

Clinical trials are facing growing complexity, often causing delays in site selection and patient enrollment. The rising cost of drug development means manual site selection can add weeks or months to studies, creating bottlenecks that slow the introduction of new therapies.

Ryght AI’s AI Site Twin platform addresses these challenges by generating dynamic digital replicas of clinical research sites. These replicas capture historical performance, patient demographics, and operational data in real-time. Sponsors and contract research organizations can use this information to identify sites that comply with protocols and regulations, forecast enrollment accurately, and streamline site activation workflows.

The collaboration will integrate Accenture’s technology, data, and industry expertise with Ryght AI’s agentic AI platform, targeting the three most critical stages of drug development: trial feasibility, site selection, and patient recruitment.

“Generative and agentic AI are transforming the foundation of clinical research,” said Petra Jantzer, PhD, senior managing director and global lead of Life Sciences, Accenture. “With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently, and with greater precision.”

Simon Arkell, CEO of Ryght AI, added, “This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched, and managed—accelerating the journey from discovery to treatment.”

Financial terms of the investment were not disclosed. The deal continues Accenture’s investment streak in biotechnology startups, including 1910 Genetics, Turbine, and Earli, which use innovative technologies to accelerate clinical trials and drug discovery.

Stay tuned for more such updates on Digital Health News